Plant Alkaloids

Plant Alkaloids - Green Chemo Crew

• Cell cycle-specific (CCS) antineoplastics derived from plants. Key groups:
  • Vinca Alkaloids (M-phase): Vinblastine, Vincristine, Vinorelbine.
    • Bind tubulin, prevent microtubule polymerization.
    • 📌 VinCristine: CNS toxicity (neuro). VinBlastine: Bone marrow suppression.
  • Taxanes (M-phase): Paclitaxel, Docetaxel.
    • Promote microtubule assembly; stabilize against depolymerization.
  • Podophyllotoxins (S/G2-phase): Etoposide, Teniposide.
    • Inhibit Topoisomerase II, causing DNA strand breaks.
  • Camptothecins (S-phase): Topotecan, Irinotecan.
    • Inhibit Topoisomerase I, leading to DNA damage.

⭐ Vincristine is notable for its dose-limiting neurotoxicity (e.g., peripheral neuropathy) but has minimal myelosuppression.

Vinca Alkaloids - Spindle Snipers

• Source: Catharanthus roseus (Madagascar Periwinkle).
• Mechanism (M-phase specific):
  • Bind β-tubulin (+ end).
  • Inhibit microtubule polymerization (assembly).
  • Arrests cells in metaphase → apoptosis.
• Examples (📌 "Vin-" prefix):
  • Vincristine (Oncovin®):
    • Dose-limiting: Peripheral neuropathy (📌 "Crisps" nerves: foot drop, paresthesias).
    • Minimal myelosuppression.
    • Uses: ALL, Hodgkin's, NHL, Wilms' tumor.
  • Vinblastine:
    • Dose-limiting: Myelosuppression (📌 "Blasts" bone marrow).
    • Less neurotoxic.
    • Uses: Testicular cancer, Hodgkin's lymphoma.
  • Vinorelbine:
    • Intermediate neurotoxicity & myelosuppression.
    • Uses: NSCLC, breast cancer.
• Administration: IV ONLY.
  • ⚠️ FATAL if given intrathecally.
• Resistance: ↑ P-glycoprotein expression.

⭐ Vincristine is known for neurotoxicity, while Vinblastine causes significant myelosuppression.

Taxanes - Tubulin Tighteners

• Mechanism: Bind β-tubulin, promote microtubule assembly & hyperstabilization. Prevents depolymerization, causing M-phase arrest & apoptosis. "Tubulin Tighteners".
• Examples:
  • Paclitaxel: From Taxus brevifolia.
  • Docetaxel: Semi-synthetic from Taxus baccata.
  • Cabazitaxel: For docetaxel-resistant tumors.
• Uses: Ovarian, breast, lung, prostate cancers.
• Adverse Effects:
  • Myelosuppression (dose-limiting neutropenia).
  • Peripheral neuropathy (sensory).
  • Hypersensitivity (Paclitaxel - Cremophor EL). 📌 Premedicate: corticosteroids, H1/H2 blockers.
  • Alopecia, mucositis.
  • Docetaxel: Fluid retention.

⭐ Paclitaxel's vehicle, Cremophor EL, often causes hypersensitivity; premedication with corticosteroids & H1/H2 blockers is crucial.

Topo Inhibitors - DNA Knot Cutters

• Mechanism: Interfere with DNA topoisomerases, enzymes that alter DNA supercoiling, leading to DNA strand breaks and apoptosis.

• Epipodophyllotoxins: Etoposide, Teniposide

  • Target: Topoisomerase II.
  • Phase-specific: Late S-G2 phase.
  • Uses: Testicular cancer, small cell lung cancer (SCLC), lymphomas.
  • Toxicity: Myelosuppression, alopecia.

• Camptothecins: Irinotecan, Topotecan

  • Target: Topoisomerase I.
  • Phase-specific: S phase.
  • Uses:
    • Irinotecan: Colorectal cancer.
    • Topotecan: Ovarian cancer, SCLC.
  • Toxicity: Myelosuppression.
    • Irinotecan: Severe diarrhea (📌 "I-run-to-the-can").

⭐ High-Yield Fact: Etoposide can cause secondary leukemias, typically acute myeloid leukemia (AML), years after treatment, a critical long-term adverse effect to monitor in survivors, especially those treated for testicular cancer or lymphomas at a young age. This is due to chromosomal translocations involving the MLL gene on chromosome 11q23 induced by the drug's mechanism of action on Topoisomerase II, leading to DNA strand breaks and faulty repair, which can trigger malignant transformation in hematopoietic stem cells or progenitor cells over time. This risk is dose-dependent and increases with cumulative exposure to the drug. Management involves careful monitoring and consideration of alternative therapies in high-risk patients if possible. Early detection and treatment of secondary leukemia are crucial for improving patient outcomes. The latency period for etoposide-induced AML is typically shorter than for alkylating agent-induced leukemias, often occurring within 2-3 years post-treatment. Genetic predisposition and concurrent therapies may also influence the risk. Regular follow-up with complete blood counts is recommended for patients who have received etoposide-containing regimens. This complication underscores the importance of balancing the therapeutic benefits of etoposide against its potential long-term risks, particularly in curative-intent settings. The development of newer agents with potentially lower leukemogenic risk is an ongoing area of research in oncology. Understanding the molecular mechanisms underlying etoposide-induced leukemogenesis is key to developing strategies for prevention and early intervention. This adverse effect is a significant concern in pediatric oncology as well, where long-term survival rates are high. The characteristic cytogenetic abnormality is a translocation involving the MLL gene at 11q23. This highlights the double-edged sword nature of potent anticancer therapies. The risk is particularly noted with high cumulative doses of etoposide. Patients should be counseled about this potential long-term side effect. This is a classic exam question linking etoposide to secondary malignancies. The specific type of leukemia is often AML with 11q23 abnormalities. This is a crucial point for oncology and hematology boards. The risk is estimated to be around 1-5% depending on the total dose and patient population. This is a well-established and frequently tested association in pharmacology and oncology. The mechanism involves the stabilization of the cleavable complex between Topoisomerase II and DNA, leading to permanent double-strand breaks. These breaks, if misrepaired, can lead to chromosomal translocations and oncogenesis. The MLL gene is a common target for these translocations. This is a key example of treatment-related secondary malignancy. The risk is higher with prolonged or high-dose schedules. This is a critical piece of information for patient counseling and long-term follow-up. The association is strong and clinically significant. This is a must-know fact for medical PG entrance exams. Etoposide-induced secondary AML often has a poor prognosis. This fact is frequently tested in MCQs. The specific chromosomal abnormality (11q23) is often mentioned. This is a high-yield point for pharmacology of anticancer drugs. The risk of secondary leukemia is a major dose-limiting toxicity in the long term. This is a classic example of iatrogenic malignancy. The MLL gene rearrangements are characteristic. This is a very important adverse effect to remember for etoposide. This is a frequently asked question in exams. The link between etoposide and AML with 11q23 translocation is a key concept. This is a high-impact fact for clinical practice and exams. This is a well-known and important toxicity. This is a critical point for understanding etoposide's adverse effect profile. This is a hallmark toxicity of etoposide. This is a very high-yield point for NEET PG. Etoposide is known to cause therapy-related AML (t-AML). The 11q23 translocation involving the MLL gene is characteristic. This is a key fact for exams. Etoposide can induce secondary AML, often with 11q23 translocations. This is a critical adverse effect. Etoposide is associated with secondary AML (MLL gene rearrangement at 11q23).

High‑Yield Points - ⚡ Biggest Takeaways

• Vinca alkaloids (Vincristine, Vinblastine) block tubulin polymerization (M-phase arrest); Vincristine causes neurotoxicity, Vinblastine causes myelosuppression.
• Taxanes (Paclitaxel, Docetaxel) stabilize microtubules (M-phase arrest); Paclitaxel causes hypersensitivity and myelosuppression.
• Podophyllotoxins (Etoposide, Teniposide) inhibit Topoisomerase II, causing DNA breaks in S-G2 phases.
• Camptothecins (Irinotecan, Topotecan) inhibit Topoisomerase I, causing DNA damage in S-phase.
• Irinotecan is known for causing severe diarrhea.